Skip to content
TRENDING
Business

IFC Supports Biovac as South Africa Begins Cholera Vaccine Trials

· 2 min read
Biovac cholera vaccine trials
Biovac cholera vaccine trials

IFC Supports Major Step in Africa’s Vaccine Manufacturing as Biovac Begins Cholera Vaccine Trials

Biovac, a South African biopharmaceutical company and long-term client of the International Finance Corporation, has started clinical trials for the country’s first locally developed oral cholera vaccine. This marks a major moment for Africa’s vaccine manufacturing ambitions and strengthens the continent’s ability to respond quickly to cholera outbreaks. If the trials progress well and approvals are granted, the vaccine could be ready for use by 2028.

The start of these trials follows three years of sustained backing from IFC, which has been instrumental in Biovac’s growth and its move toward becoming a leading manufacturer on the continent. IFC brought together a consortium of local and international development finance institutions, including South Africa’s Industrial Development Corporation and the European Investment Bank, to fund Biovac’s expansion.

In 2023, IFC committed a seven million US dollar loan, provided in rand equivalent, to support Biovac’s scale-up plans. Alongside the funding, IFC is offering advisory support for a new multi-vaccine manufacturing facility in Cape Town. The facility is expected to triple production capacity and add four to five new vaccines. It will also support both established vaccine technologies and newer mRNA platforms, strengthening Africa’s long-term health security.

This work aligns with the wider agenda of the World Bank Group, which aims to grow local vaccine and pharmaceutical production across Africa. By increasing production on the continent and supporting strong regulatory and delivery systems, these investments are designed to improve preparedness for public health emergencies and expand equitable access to lifesaving vaccines.

WRITTEN BY Nairobi Lifestyle Editor
More from Nairobi

Join the conversation

Your email address will not be published. Required fields are marked *

Keep reading

Back to home

Nairobi, straight to your inbox.

The best of the city’s events, culture, money and tech, picked by our editors.

No spam. Unsubscribe any time.